Nurix Therapeutics (NRIX) UBS Targeted Protein Degradation Day 2024 summary

Pipeline and technology overview

• Focused on targeted protein degradation using E3 ligase system, with a broad oncology and I&I portfolio.

• Lead programs include NX-5948 (BTK degrader) and NX-2127 (dual BTK/IKZF degrader), plus NX-1607 (E3 ligase inhibitor).

• Multiple strategic partnerships with Gilead, Sanofi, and Pfizer, expanding reach in oncology and autoimmune disease.

• Degrader molecules are also being developed as ADC payloads in collaboration with Pfizer.

Key clinical updates and development plans

• Next data disclosure for NX-5948 expected in the second half of the year, focusing on CLL and NHL.

• Pivotal trials for NX-5948 targeted to start in 2025, with Fast Track designation in post-BCL-2, post-BTK inhibitor CLL.

• Updates on NX-1607 and partnership programs are anticipated periodically, with expansion strategy to be discussed by year-end.

NX-5948 clinical data and differentiation

• In heavily pre-treated CLL patients, NX-5948 showed a 70% objective response rate and excellent safety profile.

• Demonstrated CNS penetration and efficacy, with responses in patients with CNS involvement.

• Potential to address resistance mutations and offer improved durability over current BTK inhibitors.

• Plans for single-arm pivotal trial and randomized confirmatory trials, including combination regimens.